890 related articles for article (PubMed ID: 29317554)
1. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
2. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
[TBL] [Abstract][Full Text] [Related]
3. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study.
Mondello P; Steiner N; Willenbacher W; Wasle I; Zaja F; Zambello R; Visentin A; Mauro E; Ferrero S; Ghione P; Pitini V; Cuzzocrea S; Mian M
Ann Hematol; 2016 Jun; 95(7):1107-14. PubMed ID: 27103007
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
7. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
8. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma.
Hill BT; Nastoupil L; Winter AM; Becnel MR; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Fakhri B; Reddy P; Smith SD; Mukhija D; Jagadeesh D; Desai A; Alderuccio JP; Lossos IS; Mehra P; Portell CA; Goldman ML; Calzada O; Cohen JB; Hussain MJ; Ghosh N; Caimi P; Tiutan T; Martin P; Kodali A; Evens AM; Kahl BS
Br J Haematol; 2019 Feb; 184(4):524-535. PubMed ID: 30575016
[TBL] [Abstract][Full Text] [Related]
9. [Follicular lymphoma: first - line selection criteria of treatment].
Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
[TBL] [Abstract][Full Text] [Related]
10. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
[TBL] [Abstract][Full Text] [Related]
11. Modified R-BAC plus BTK inhibitor regimen in newly diagnosed young patients with mantle cell lymphoma: a real-world retrospective study.
Li W; Chang Y; Liu X; Chen Z; Sun J; Geng Z; Zhang M; Zhang L
Ann Hematol; 2024 Jun; 103(6):2003-2012. PubMed ID: 38308020
[TBL] [Abstract][Full Text] [Related]
12. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial.
Watanabe T; Tobinai K; Wakabayashi M; Morishima Y; Kobayashi H; Kinoshita T; Suzuki T; Yamaguchi M; Ando K; Ogura M; Taniwaki M; Uike N; Yoshino T; Nawano S; Terauchi T; Hotta T; Nagai H; Tsukasaki K;
Lancet Haematol; 2018 Nov; 5(11):e520-e531. PubMed ID: 30389034
[TBL] [Abstract][Full Text] [Related]
13. Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Peñalver FJ; Márquez JA; Durán S; Giraldo P; Martín A; Montalbán C; Sancho JM; Ramírez MJ; Terol MJ; Capote FJ; Gutiérrez A; Sánchez B; López A; Salar A; Rodríguez-Caravaca G; Canales M; Caballero MD;
Cancer Med; 2019 Nov; 8(16):6955-6966. PubMed ID: 31573746
[TBL] [Abstract][Full Text] [Related]
14. Comparison of first-line treatment with bendamustine plus rituximab versus R-CHOP for patients with follicular lymphoma grade 3A: Results of a retrospective study from the Fondazione Italiana Linfomi.
Margiotta-Casaluci G; Bigliardi S; Cocito F; Meli E; Petrucci L; Nicolosi M; Annibali O; Boccomini C; Bozzoli V; Castellino A; Cattina F; Cenfra N; Ciavarella S; Kovalchuk S; Rotondo F; Fama A; Olivieri J; Zaja F
Front Oncol; 2023; 13():1120967. PubMed ID: 36969038
[TBL] [Abstract][Full Text] [Related]
15. A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL).
Boccomini C; Ladetto M; Rigacci L; Puccini B; Rattotti S; Volpetti S; Ferrero S; Chiarenza A; Freilone R; Novo M; Corradini P; Nassi L; Rusconi C; Stelitano C; Bolis S; Marina Liberati A; Tucci A; Baldini L; Balzarotti M; Evangelista A; Ciccone G; Vitolo U
Br J Haematol; 2021 Apr; 193(2):280-289. PubMed ID: 33476434
[TBL] [Abstract][Full Text] [Related]
16. Ki67 proliferation index in follicular lymphoma is associated with favorable outcome in patients treated with R-CHOP.
Nichols MM; Ondrejka SL; Patil S; Durkin L; Hill BT; Hsi ED
Leuk Lymphoma; 2023; 64(8):1433-1441. PubMed ID: 37226602
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
18. Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi.
Nizzoli ME; Manni M; Ghiggi C; Pulsoni A; Musuraca G; Merli M; Califano C; Bari A; Massaia M; Conconi A; Musto P; Mannina D; Perrone T; Re F; Galimberti S; Gini G; Capponi M; Vitolo U; Usai SV; Stefani PM; Ballerini F; Liberati AM; Pennese E; Pastore D; Skrypets T; Catellani H; Marcheselli L; Federico M; Luminari S
Hematol Oncol; 2023 Oct; 41(4):655-662. PubMed ID: 37246287
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M
J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677
[TBL] [Abstract][Full Text] [Related]
20. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
Barr PM; Li H; Burack WR; LeBlanc M; Smith SM; Gopal AK; Floyd JD; Persky DO; Press OW; Fisher RI; Friedberg JW
Lancet Haematol; 2018 Mar; 5(3):e102-e108. PubMed ID: 29396094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
